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Treatment of TB
In the Spring of 2003, the American Thoracic
Society (ATS), Infectious Diseases Society of
America, and Centers for Disease Control and
Prevention (CDC) issued updated guidelines
for the treatment of tuberculosis (TB).1 These
guidelines are substantially longer and signifi-
cantly more comprehen-
sive than the prior
ATS/CDC guidelines pub-
lished in 1994.2 The docu-
ment is a guideline for the
treatment of TB disease
only and does not include
management of latent TB
infection (LTBI). 
There are some notable
differences between the
revised guideline and the 1994 treatment state-
ment. The revised guideline strongly empha-
sizes that 1) the responsibility of successful
treatment of TB rests with the provider rather
than the patient and 2) case management
should be patient-centered, with direct obser-
vation of therapy as the strongly preferred
method of administration of medicines.
The document has a complete discussion of
the drugs currently available to treat TB, includ-
ing dosing, dose adjustments needed for renal
or hepatic dysfunction, toxicities, management
of common adverse effects and information
about interactions between antituberculars and
other drugs. Because rifamycins have the
potential for drug-drug interactions with numer-
ous agents, there is special attention to this
class of drugs. It also discusses treatment
issues in special groups, such as children and
pregnant and breast-feeding women.
According to the guidelines, treatment comple-
tion is now determined by the number of doses
delivered, as well as the duration of therapy.
Also included is an algorithm on how to man-
age treatment interruption, a problem that is not
uncommon.
Among patients with TB caused by drug-sus-
ceptible organisms, those with cavitary pul-
monary disease on the initial chest radiograph
and/or a sputum specimen that is still culture
positive for Mycobacterium  tuberculosisat the
completion of the initial two-month phase of
treatment have been shown to be at increased
risk of relapse. In patients with both of these
risk factors, the rate of relapse disease
is further increased.
Accordingly, the guide-
lines recommend that
the continuation phase of
therapy be prolonged
from four to seven
months in patients with
both risk factors.
Patients having just one
of these risks do not
need to be treated with
an extended continua-
tion phase, but should be
monitored closely for signs of a poor response
to therapy and have treatment extended if there
is not a prompt response to treatment. In order
to identify patients at risk for relapse, culture of
sputum specimens should be obtained in all
patients with pulmonary disease at the comple-
tion of the initial two-month phase of therapy.
As a result of clinical trials examining the use of
the long-acting rifamycin rifapentine for the
treatment of TB, recommendations for its use
are now included in the guideline. Because of
the drug's extremely long half-life, it can be
used once-weekly, making it an attractive
option for supervised regimens. Once-weekly
dosing of isoniazid and rifapentine is now
included as a choice for the continuation phase
of treatment in patients who meet the following
criteria: 1) HIV-uninfected 2) non-cavitary, pul-
monary TB, 3) M. tuberculosisthat is drug-sus-
ceptible, and 4) sputum specimens are smear
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Tuberculosis Update 2004
“The responsibility of
successful treatment of
TB rests with the
provider rather than 
the patient.”
negative for acid-fast bacilli at the end of
the initial phase of treatment. Patients with
advanced TB disease or HIV infection have
increased risk treatment failure and
relapse when treated with highly intermit-
tent regimens. Once-weekly treatment with
rifabutin should never be used in these
patients.
Treatment of TB in those with HIV infection
is also addressed by the guidelines. Some
patients with HIV infection are at risk for
emergence of TB caused by organisms
with rifamycin resistance when treated with
intermittent regimens. Because of reports
of disease caused by rifampin-resistant
organisms in persons with advanced HIV
infection, persons with CD4 counts less
than 100 should not be treated with twice-
weekly regimens and should receive med-
ications daily or three times weekly. As
stated above, no one with HIV infection
should receive once-a-week treatment. 
QuantiFERON®-TB Test
This year CDC issued guidelines for the
use of QuantiFERON®-TB test.3 The
QuantiFERON®-TB (QFT) test was
approved by the Food and Drug
Administration in 2001. Like the tuberculin
skin test (TST), this test is used to aid in
the detection of LTBI. This test measures
the production of interferon-gamma and is
an in vitrocytokine-based assay to detect
cell-mediated immune reactivity to M.
tuberculosis.  Unlike a TST, this assay
requires phlebotomy, can be completed
with only a single patient visit, can assess
and distinguish between responses to both
M. tuberculosis and environmental
mycobacteria, and does not boost amnes-
tic immune responses. It appears that
interpretation of the whole-blood interferon
gamma assay is less subjective than the
TST and that it may be less affected than
TST by prior BCG vaccination, reactivity to
nontuberculous mycobacteria, and reader
error.4
The characteristics of the test that make it
appealing as a screening tool include the
ability to distinguish between M. tuberculo-
sis and other mycobacteria, need for a sin-
gle patient visit and less interference from
BCG vaccination. In its recommendations
for QFT, CDC suggests that this test be
considered for LTBI screening of persons
at increased risk of having or acquiring
LTBI, including residents and employees of
correctional facilities, injection drug users,
recent immigrants, and some health care
workers. 
There are, however, several significant lim-
itations to the use of this test. For example,
it should not be used in persons with
symptoms of TB since TB disease is asso-
ciated with suppressed interferon-gamma
responses. It should also not be used in
children, pregnant women, those with HIV
infection or other clinical conditions that
increase the risk of progressing from LTBI
to TB disease, or in the context of contact
investigations since the appropriate use of
the test in these situations and populations
has not been defined. It also should not be
used within 12 months of the administra-
tion of a TST, as the injection of purified
protein derivative can affect the results of
QFT. These limitations will probably make
the use of this tool difficult in some settings
where frequent screening takes place,
such as correctional facilities. Further data
on appropriate use of the test is needed
and will be helpful to determine the settings
and populations where this test can be best
used.
Revised Recommendations
for the use of Rifampin
and Pyrazinamide for the
Treatment of LTBI
Following an earlier recommendation that
two months of rifampin and pyrazinamide
(RZ) could be used as an option for the
treatment of LTBI5, cases of severe liver
injury were noted among patients who
received this regimen. CDC issued cau-
tions to providers and recommended
enhanced monitoring for patients receiving
RZ. From October 2000 through June
2003, 48 patients with severe liver injury
were reported in the U.S. Eleven of these
patients died.6-8
In a report published in August 2003, CDC
reported the results of surveillance con-
ducted on patients who received RZ from
January 2000 through June 2002 to esti-
mate the risk of severe liver injury associ-
ated with this regimen.9 Of the 7,737
patients who received RZ, 204 discontin-
ued treatment because of aspartate amino-
transferase serum concentrations that
exceeded five times the upper limit of nor-
mal, (26.4 per 1,000 treatment initiations,
95% CI 22.8-30.0). RZ use was stopped in
146 more patients due to symptoms of
hepatitis (18.9 per 1,000 treatment initia-
tions, 95% CI 17.4-20.4). There were 30
cases of severe liver injury in the cohort,
defined as hospitalization or death of the
patient. Seven of these patients died, giv-
ing estimated rates of hospitalization and
death of 3.0 (95% CI 1.8-4.2) and 0.9 (95%
CI 0.2-1.6), respectively, per 1,000 treat-
ment initiations. These rates are signifi-
cantly higher than seen in recent studies
examining adverse events associated with
isoniazid for the treatment of LTBI, where
median hospitalization and death rates
h ve been reported to be 0.15 and 0.04 per
1,000 treated, respectively.
Based on these high rates of adverse
effects, hospitalization and death, ATS and
CDC have changed the official recommen-
dation for the use of RZ, and now state that
this regimen generally should not be
offered to patients, including patients with
or without HIV infection. Isoniazid should
be the first choice for treatment of LTBI.
Rifampin alone should be used for patients
suspected to be infected with M. tuberculo-
sis resistant to isoniazid.
Use of Rifamycins for the
Treatment of TB among
HIV-Infected Patients
Receiving PIs or NNRTIs
Protease inhibitors (PIs) and non-nucleo-
side reverse transcriptase inhibitors
(NNRTIs) are metabolized by the hepatic
enzyme CYP3A4. Because rifamycins
induce the activity of this enzyme, there are
substantial decreases  in serum concentra-
tions of these antiretroviral drugs when
they are co-administered with rifamycins.
The rifamycins differ in the degree to which
CYP34 is induced; rifampin is the most
p tent followed by rifapentine and then
rifabutin. Since PIs and NNRTIs, depend-
ing on the agent, can inhibit or induce this
same enzyme, it is difficult to predict the
drug-drug interactions that will occur when
these agents are co-administered. With the
addition of new antiretroviral agents or new
combinations of antiretroviral agents (such
as those used for pharmaco-enhancement)
to the therapeutic armamentarium, and lim-
ited published studies on the pharmacoki-
netics of these drug-drug interactions, it is
a therapeutic challenge knowing how to
optimally administer these medications to
patients with both HIV infection and TB.
Despite periodic updates of recommended
dose adjustments for concurrent use of
anti-TB and antiretroviral medicines,10,11
there is a need to present updated infor-
mation to providers as new data become
available. The CDC now maintains a
website www.cdc.gov/nchstp/tb/TB_HIV
_Drugs/TOC.htm, where this information
will be updated on a continuing basis. This
contains text, tables with recommendations
of which rifamycins can be used with PIs
and NNRTIs and dose adjustments needed
for drugs that can be used together. 
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"Those who cannot remember the past are condemned to repeat it." 
George Santayana, philosopher and poet
Dear Colleagues: 
Consider the following from the recent report to congress entitled “The Health Status Of Soon To
Be Released Inmates”:
-The prevalence of latent tuberculosis infection (LTBI) among inmates is markedly increased 
compared to the general population.  
-Nationwide, >500,000 inmates with LTBI are released each year.
-The rate of active tuberculosis in jails is fifteen times that seen in the general population.
-One-third of those with active tuberculosis in this country have been recently incarcerated.
-Approximately 15% of those with HIV in this country have been recently incarcerated.
Unfortunately, it has become all too easy in the U.S. to become complacent about tuberculosis.
A marked decrease in new cases over the past 30 years has led to a situation in which many clin-
icians rarely, if ever, encounter a case of active disease. In the U.S. correctional setting, we treat
a disproportionate number of individuals who are infected with HIV and/or MTB. Those coinfect-
ed with these two pathogens are at a significantly increased risk for progressing from LTBI to
active contagious disease. Just one such individual in an overcrowded, underventilated congre-
gate living environment can quickly lead to an outbreak situation among staff, inmates, and visi-
tors. Those who are latently infected can be identified and treated while incarcerated, preventing
the future development of active disease and transmission to others. It is unlikely that this nation
will achieve its TB elimination goals without the efforts of all of us who work in correctional set-
tings.  
This month, Deputy Editor Renee Ridzon (currently with the Bill and Melinda Gates Foundation
and formerly of the CDC TB control branch) provides an update of new information in the field f
tuberculosis. This month's HIV 101 is an extremely useful table for clinicians detailing dosing
interactions between rifamycins and antiretroviral agents, while our spotlight focuses on the use
of electronic medical records in the correctional healthcare setting.
Next month, a trio of HEPP Report editors will bring you the latest in information from this year's
conference on retroviruses and opportunistic infections, to be held in San Francisco February 8-
11.  Thank you for your ongoing readership of HEPP Report, and please let us know how we can
better serve you in the future.  
Sincerely, 
Joseph Bick, MD
Letter from the Editor
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It's Friday afternoon. The director of your Department of
Corrections has been summoned to testify before the legislature
on Monday morning concerning the correctional health care bud-
get. You have been given one hour to provide her with the follow-
ing information:  
-complete outcome data for all patients evaluated and treated for
hepatitis C in the past 18 months
-HIV-infected patients stratified by nadir and most recent T cell
count, viral load, and current HAART regimes
-percentage of your diabetic patients who received urine protein
screening, podiatric evaluation, and hemoglobin A1C monitoring
within the past year 
-total expenditures by drug for the twenty most costly medications
on your formulary.   
You: 
a) freeze the gate, and put all available staff to work pouring over
your paper medical records 
b) decide to accept that early retirement you have been contem-
plating  
c) query your EMR and obtain all the requested data (and more)
within the time allotted. 
The effective medical management of any chronic illness depends
upon the ability to record and recall data.  In addition, reimburse-
ment and risk management often hinge upon the maintenance of
an accurate, complete medical record. As treatments become
more complex, it has become increasingly difficult to accomplish
these tasks solely through the use of a paper record.  In response
to these growing demands, a wide variety of electronic medical
record (EMR) systems have been created.  EMRs are being used
for charting, to remind clinicians when patients with chronic ill-
nesses such as HIV, diabetes, or hypertension need routine test-
ing, to schedule healthcare appointments, to prompt clinicians to
order lab work and vaccinations, and to record data in a way that
it can be accessed and manipulated by health care providers.
EMRs can simplify the movement of data for patients who are
seen by multiple clinicians at many different facilities. It has been
estimated that between 10 and 20 percent of physicians in this
country are currently using EMRs. 
Alth ugh some clinicians have been slow to embrace these new
technologies, the federal government may accelerate the use of
EMRs by requiring them as a condition of participation in programs
such as Medicare. In 2001, the Institute of Medicine (IOM) pub-
lished a report outlining obstacles to the provision of quality health-
care. The IOM specifically recommended the use of information
technology to address organizational deficiencies in the treatment
of chronic conditions. The American Academy of Family Practice
has announced a goal of having electronic medical records in
place by 2006. The academy is evaluating a number of web-based
syst ms, and believes that an EMR will reduce medical errors,
improve safety, increase screening and preventive care, reduce
complications including drug errors, and facilitate the introduction
of evidence-based guidelines.    
Although most of the commercially available EMR systems have
been designed to comply with the Health Insurance Portability and
Accountability Act, (HIPPA), security of web-based systems con-
tinu s to be of paramount concern.  For this reason, some health
organizations have chosen to maintain all information on a local
server.  Some clinicians have not embraced EMRs because of the
start-up cost involved or concerns about the need for ongoing
l gistical support.  Furthermore, converting paper records to elec-
tronic format can be a daunting task.  With recent technological
improvements, it is now possible to scan electronically existing
medical records, simplifying the conversion process to an EMR.
Once an EMR is in place, clinicians can input medical information
using a personal computer or a notepad-sized wireless personal
digital assistant (PDA). 
Joseph Bick*, MD, Julia Noguchi**, MA
Spotlight: Electronic Medical Records (EMRs) in Corrections
Continued on page 5
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What follows are comments on some of the EMRs currently being
used in correctional settings around the country. Rather than being
an exhaustive review, this spotlight is intended to stimulate dis-
cussion and information sharing concerning information technolo-
gies among our correctional colleagues.  We encourage feedback
from readers about systems in use in jail or prison settings around
the country. 
Emerald
Dr. David Paar of the University of Texas
Medical Branch utilizes an EMR that he
describes as an "in house" custom designed
program called Emerald. With Emerald, the
ordering physician views a menu and enters
a request for labs to be drawn. Once
obtained, the results of these tests are then
entered into the system and emailed to the
ordering physician.  Dr. Paar notes the con-
venience of an integrated electronic system
whereby the physician simply clicks on a
patient's chart and puts lab results into con-
text.  Dr. Paar suggested the need for a sim-
ilar system for radiographs and other imag-
ing studies.  "We shouldn't limit our thinking
to just laboratory values. This concept could
be applied to other studies to manage all
diagnostic tests and biopsies, such as chest
x-rays, so all of these test results could come
back in timely fashion."  
Serapais®
Dr. Lou Tripoli of the Correctional Medical
Institute uses Serapais®, an EMR that has
been modified for the correctional setting.
Serapais® allows the user to search a patient by name, inmate #,
account #, DOB, and SSN. This system can capture detailed
patient information including demographics, problem lists, health
assessments, and test results. It provides alerts for identifying
potentially chronically ill patients during the health screening
process and sends out reminders for appointments, test prepara-
tions and test results. Moreover, Serapais® generates SOAP or
"Subjective, Objective, Assessment and Plan" notes during patient
encounters with the healthcare provider. Accordingly, this system
not only offers the "four building blocks" required for an effective
EMR, but also effectuates the final step whereby the progress
notes are generated electronically. 
Quest Diagnostics® TORO
Dr. Joseph Paris of the Georgia D.O.C. uses a system developed
by Quest Diagnostics® called TORO. His correctional facility opted
for a vendor with an extensive server that has the capacity to store
medical information for tens of thousands of inmates.  For a given
correctional facility to reproduce these data is not only time-con-
suming, but expensive. TORO allows providers to access their
own database that is housed on Quest's server by paying a very
reasonable surcharge.  According to Dr. Paris, the biggest advan-
tage of this EMR is instant laboratory data retrieval. Although
TORO does not presently have plotting capabilities that can graph
specific results, Dr. Paris feels that this feature, which will be avail-
able in the near-future, will further improve upon what is already an
excellent system. 
Labtracker
Lab Tracker™ from Ground Zero Software (info@labtracker.com)
is a full-purpose electronic medical record (EMR) with disease-
specific programming for HIV and other infectious diseases,
including hepatitis.  The database platform was originally devel-
oped as a way to manage and graph labora-
tory results and medications specific to HIV,
and has since become an all-inclusive EMR.
The platform currently houses records for 10
percent of HIV patients in the U.S. through
institutions such as Emory University and the
University of Miami, and two-thirds of all
hemophilia patient records in the U.S.
through coordinated efforts of Baxter
Bioscience and the CDC.  
What follows are case examples of
three   representative installations: statewide
(Louisiana), regional (Owen Clinic at the
University of California at San Diego), and an
individual facility (Cape Vincent Correctional
Facility in New York).
State of Louisiana
The Health Care Services Division (HCSD) of
Louisiana State University Health Sciences
Center comprises eight state hospitals.
A wide-area network (WAN) of shared
servers connects the healthcare center in
New Orleans to geographically dispersed
hospitals.  
New Orleans implemented a customized version of Lab Tracker for
HIV-infected patients in May 2003.  Currently, four hospitals use
Lab Tracker to accommodate approximately 5,000 unique patient
files.  The Lab Tracker initiative is led by Newton E. Hyslop, Jr. MD,
Clinical Lead of LSU HCSD's HIV Disease Management Initiative,
and Nathan Daigrepont, Lab Tracker Project Coordinator.
Prior to Lab Tracker, providers had to retrieve information from
several different systems and sources for a complete patient pro-
file. Daigrepont says the criteria for the new EMR were ambitious
in scope, and included a single database that integrated all SOAP
notes, radiology, laboratories, clinics, and pharmacies.
Lab Tracker data integration and data mining capabilities were a
key product differentiator, according to Daigrepont.  At the patient
level, Lab Tracker provides graph and trend analysis using linear
plots and logarithmic scales to show how, for example, a given
patient's CD4 counts or viral loads have responded by medication,
dosage and other variables over time. The visual image can be
used as an education tool to encourage patient adherence. At pre-
sent, 300 laboratory tests have been validated for the system.
Medication data is uploaded from a pharmacy database.
Modifications are underway to automate medication entry, as well
as simplify SOAP notes entry with optional voice recognition.
When fully integrated, graph and trend analysis are expected to
Spotlight...(continued from page 4)
“Electronic Medical
Records (EMRs) may
reduce medical errors,
improve safety,
increase screening and
preventive care,
reduce complications
including drug
errors, and facilitate
the introduction of 
evidence-based 
guidelines.”
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significantly reduce the amount of time needed to retrieve records,
analyze patient health, and prepare for patient visits. Lab Tracker
has recently added screens that will allow clinicians to more effec-
tively track hepatitis data. These screens provide "at a glance"
information to clinicians, which will be useful in avoiding unneces-
sary repetition of tests and procedures.  
At a statewide level, the ability to bring together disparate patient
files in a single uniform database will enable LSU HCSD to
improve utilization management from a central location.  It will be
possible to conduct costs analyses budgetary forecasts and
access patient data archives to assess needs for improvements for
patients who are failing treatment or falling out of care. 
Under the auspices of Special Projects of National Significance
grant from the U.S. Department of Health and Human Services,
LSU HCSD is conducting an analysis of the impact of introducing
Lab Tracker as a medical record system to the LSU HCSD HIV
Clinics.
Owen Clinic
The Owen Clinic at the University of California San Diego Health
Center has been using Lab Tracker since 1997. Approximately
9,000 unique patient files dating back more than 10 years are
housed in the EMR, of which 2,000 are active files. 
Since 2000, the Liver Clinic has been using a version of Lab
Tracker tailored to hepatitis and liver cancers for approximately
5,000 patient files. More recently, the Mother, Child & Adolescent
HIV Clinic implemented a pediatric version of Lab Tracker in 2002
to help manage its 500 patient files.  Presently, each clinic runs its
own versions on separate servers with the option to share data as
needed.
At the Owen Clinic, physicians have reduced preparation time
using Lab Tracker to access patient histories and SOAP notes,
and enhanced patient visitations with the visual snapshots of
patient progress using graph and trend analysis. The clinic uses
Lab Tracker's analytical capacity to compile internal reports on a
variety of factors, including longitudinal studies based on CD4
counts or viral loads, and cross-sectional studies, such as the most
recent Hepatitis C status.
Cape Vincent Correctional Facility
The Cape Vincent Correctional Facility in New York is an example
of how Lab Tracker can benefit healthcare at smaller, individual
sites.  Attending physician Dr. Charles Moehs is a family physician
who has worked in corrections for 10 years and is a member of the
American Association of HIV Medicine.  Of the total Cape Vincent
population of 900 to 1,100 inmates, Moehs sees approximately 75
HIV and hepatitis C patients on a regular basis.
Prior to Lab Tracker, Moehs handled records by hand.  Patient
charts would be circulated among many places and difficult to
locate.  At times he went into patient visits without knowing
whether the patient was adherent. In order to bring order to the
process, he began entering patient data in Microsoft Excel.  He
sought an EMR that enabled him to sort and conduct population
trends; the program had to be intuitive, simple to install and easy
to use.
Moehs has used Lab Tracker since 1999.  The EMR converted all
existing Excel data, allowing him to begin entering additional data
immediately and customizing the program to fit his needs.  He esti-
mates a new patient profile takes 15 minutes to create, and that his
preparation and analysis time has been reduced to about five min-
utes per patient encounter.
According to Moehs, the biggest benefit of Lab Tracker has been
its graph and trend analysis. It provides him an instant snapshot of
CD4 counts, viral loads and other key indicators in relation to cur-
rent and new medications. Moehs believes that the graphs have
enhanced the patient-provider relationship. When a patient can
see a graph of his progress, the level of trust in both the clinician
and the treatment improves. As research by HEPP Report's Dr.
Rick Altice has demonstrated, these are two of the main factors
predicting patient adherence. Lastly, Lab Tracker has improved the
patient discharge process.  Moehs can provide a complete packet
of pertinent patient information and medication records so that
released inmates experience a more seamless transition in con-
tinuing treatment at an outpatient clinic.
Conclusions
Regardless of institutional size, correctional health care providers
can benefit from an all-purpose EMR.  At smaller facilities, an EMR
can enhance the quality of provider service, improve levels of
patient trust and adherence, and streamline the discharge
process. At a regional level, an EMR can provide integrated
records management that links hospitals, clinics, laboratories and
pharmacies in one uniform database.  In its clinical capacity, an
EMR can save time in preparation and analysis, allowing doctors
to offer equal level of care more effectively.  
High-level outcome studies can enable administrators to manage
chronic diseases by indicators.  The statewide example of the
Health Care Services Division at Louisiana State University indi-
cates that a fully networked EMR can significantly improve utiliza-
tion management from a central location.  Once direct data entry
by providers of critical information such as medications and immu-
nizations is implemented, an EMR's potential ability to perform any
number of outcomes studies will ease the burden of conducting
cost analyses and budgetary forecasts.  
Additional considerations for corrections facilities in particular are
that improved records management can reduce the expenses
associated with unnecessarily repeating studies on patients who
have moved from one facility to another. Better archival and
records management can also improve litigation management and
correspondence with a state's Medical Board. Most importantly, an
EMR enables healthcare providers to improve care, ease the tran-
sition of records to new providers, and reduce the human toll of
outdated bureaucratic information flow.  
DISCLOSURES:
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7HIV 101: Guidelines for the Use of Rifamycins for the Treatment of           
Tuberculosis in Patients Taking PIs or NNRTIs*
Ritonavir
Amprenavir
Fos-Amprenavir
Atazanavir
Indinavir
Nelfinavir
Saquinavir
Saquinavir / 
ritonavir
Lopinavir / riton-
avir (Kaletra®)
Efavirenz
Nevirapine
Delavirdine
PI/ NNRTI
dose change 
None
Saquinavir
400 mg +
ritonavir 400
mg bid
Rifampin and
lopinavir/
ritonavir
(Kaletra®)
should not 
be used
together.  
h to 800
mg/day
May i to 600
mg/day if 800
mg dose not
easily 
tolerated.
200 mg
twice-daily
Rifampin and amprenavir
should not be used together.
Rifampin and fos-amprenavir
should not be used together.
Rifampin and atazanavir
should not be used together.
Rifampin and indinavir
should not be used together.
Rifampin and nelfinavir
should not be used together.
Rifampin and saquinavir
should not be used together.
Rifampin and delavirdine
should not be used together.
Ritonavir (any dose) with saquinavir, indinavir, amprenavir, fos-amprenavir,
or atazanavir
Rifabutin and non-boosted
saquinavir should not be used
together.
Rifabutin and delavirdine should
not be used together.
Rifampin
dose change
None 
(600 mg/day)
None (600
mg/day)
None (600
mg/day)
None (600
mg/day)
None (600
mg/day)
Comments
Ritonavir AUC i by 35%;
no change in rifampin
concentration.
Amprenavir AUC i by
82%, Cmin i by 92%.
See amprenavir
Interaction studies not
performed, but marked
decrease in atazanavir
concentrations predicted.
Indinavir AUC i by 89%.
Nelfinavir AUC i 82%.
Saquinavir AUC i by
84%.
Limited clinical 
experience
Lopinavir AUC i by 75%
& Cmin i by 99%.
Limited clinical experi-
ence. Increased hepato-
toxicity from ritonavir is
likely.
Efavirenz AUC i by 22%;
no change in rifampin
concentration. 
Nevirapine AUC i 37-
58% and Cmin  i 68%
with 200 mg 2x/day dose.
Limited, though favor-
able, data for 200 mg
BID. Should only use if
no other options exist
and clinical and virologic
monitoring possible.
Delavirdine AUC i by
95%.
PI dose
change
None
None
None
None
h to
1000
mg q8h
h to
1000
mg q8h
None
None
None
None
Rifabutin dose
change
i to 150 mg/day or
300 mg every other
day or 150 mg
3x/week
i to 150 mg/day or
300 mg 3x/week 
i to 150 mg/day or
300 mg 3x/week
i to 150 mg every
other day or 150 mg
3x/week 
i to 150 mg/day or
300 mg 3x/week
i to 150 mg/day or
300 mg 3x/week
i to 150 mg every
other day or 150 mg
3x/week
i to 150 mg every
other day or 150 mg
3x/week
h to 450 mg/day or
600 mg 3x/week
300 mg/day or 300
mg 3x/week
Comments
Rifabutin AUCh by
430% no change in
ritonavir concentra-
tion.
Rifabutin AUC h by
193%; no change in
amprenavir concen-
tration.
Comparable to
amprenavir.
Recommendation as
per package insert.  
Rifabutin AUC h by
250%.
Rifabutin AUC h by
204%; indinavir AUC
i by 32%.
Rifabutin AUC h by
207%; nelfinavir AUC
i by 32%.
Saquinavir AUC i by
43%.
Rifabutin AUC h by
303%; 25-O-des-
acetyl rifabutin AUC
h 47.5-fold.
Rifabutin AUC i by
38%.  Effect of
efavirenz + protease
inhibitor(s) on
rifabutin concentra-
tion has not been
studied.
Rifabutin and nevi-
rapine AUC not sig-
nificantly changed.
Delavirdine AUC i
by 80%; rifabutin
AUC h by 100%.
*Updated January 20, 2004. Adapted from the Centers for Disease Control and Prevention: http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/Table1.htm 
http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/Table2.htm
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RIFAMPIN
SINGLE PROTEASE INHIBITORS (PIS)
DUAL PROTEASE-INHIBITOR COMBINATIONS
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)
RIFABUTIN
The 11th Conference on
Retroviruses and Opportunistic
Infection
February 8-11, 2004
San Francisco, CA
Contact: Office of the Retrovirus
Conference Secretariat
Call: 703.535.6862
Fax: 703.535.6899
Email: info@retroconference.org
Visit: www.retroconference.org
8th North American Region
Conference of the International
Union Against Tuberculosis and
Lung Disease 
February 26-28, 2003
Austin, TX 
Themes will include Global
Threats to Regional TB; 
Cross-Border TB Issues;
Treatment Strategies and
Disparities of TB Control in Low-
Incident Countries; and Scientific
Challenges for TB Control:
Resistance, Drug Discovery, and
Laboratory Methods. 
Call: 312.243.2000
Fax: 312.243.3954 
Email: TB@alamc.org 
Visit: www.lungchicago.org 
or www.iuatld.org
Antiretroviral Update 2004
March 16, 2004
12:30 PM  -  3:30 PM EST
Sponsored by 
Albany Medical College
CME and Nursing credits available
Call: 518.262.4674
Email: ybarraj@mail.amc.edu 
Visit: www.amc.edu/Patient/
hiv/hivconf/index.htm
National HIV/AIDS Update
Conference
March 27-30, 200
Hyatt Regency, Miami, FL
Sponsored by amfAR
To register contact Jessica Bush
jessica@fa-events.com
NCCHC: Clinical Updates in
Correctional Health Care
May 22-25, 2004
Hyatt Regency, Chicago, IL
The NCCHC and Academy of
Correctional Health Professionals
are calling for abstracts. 
Call: 773.880.1460
Fax: 773.880.2424
Visit: www.ncchc.org
Save the 
Dates
8
Tipranavir: Phase II Study, 80-week 
Follow-up
A study presented at the 9th European AIDS
Conference evaluated the durability of TPV-
based therapy in PI-experienced patients.
Patients were randomized to either low-dose or
high-dose ritonavir-boosted (100mg) TPV, plus
efavirenz and one new NRTI. After 16 weeks on
therapy both dose groups achieved full viral sup-
pression, which appears to be fully maintained in
terms of log change in viral load at week 80: -2.43
log for high dose and -2.55 for low dose. Using
on-treatment analysis, 90% on high dose and
43% on low dose had <50 copies/ml at week 80.
In low-dose patients 90% had <50 copies/ml at
week 48, but this fell to 43% at week 80. Using
<400 copy test, 90% using high dose and 64%
using low dose had undetectable VL. Median
increases in CD4+ cell counts were +143 for high
dose group and +175 for low dose group. Results
indicate that TPV-based therapy can provide a
durable response in the majority of PI-experi-
enced patients.
Long-term 80-week follow-up of highly treat-
ment-experienced (HTE) patients on tripranavir-
based antiretroviral therapy. (BI 1182.2)
Boehringer Ingleheim Pharmaceuticles, Inc. et
al.  9th European AIDS Conference (EACS)
October 2003.
Bristol-Myers-Squibb Announces $30 Million
in Grants for Africa
BMS announced that it will allocate six new pro-
gram grants totaling $30 million as part of the
Secure the Future initiative to fight HIV/AIDS in
Africa. The program focuses on funding pro-
grams at community and medical centers in
Botswana, Nambia, Lesotho, Swaziland, and
South Africa, the country most devastated by the
HIV/AIDS epidemic. Secure the Future works to
develop sustainable models in resource-limited
settings for community-based initiatives, building
internal resources and infrastructure and imple-
menting modern science within a local context. 
NATAP - www.natap.org
Trinity Biotech's Rapid HIV Test Gets U.S.
Approval
Trinity Biotech has announced that Uni-Gold
Recombigen, already in use in Africa, has been
approved in the U.S. for the detection of antibod-
ies to HIV in human serum, plasma or whole
blood. The product requires only one step, pro-
duces a result within 10 minutes, and can be con-
ducted in a doctor's office. Studies have shown
that as many as 40% of those taking HIV tests do
not return for their results. Rapid testing methods
have the potential to increase the likelihood that
those who are tested will receive their results.
NATAP - www.natap.org
Study: Oral Sex Not Linked to HIV Risk
I  a ten-year couples study, a cohort of 135 HIV-
negative (110 women and 25 men) Spanish het-
erosexuals in a sexual relationship with an HIV-
positive partner were evaluated. Of the women,
96 had performed fellatio on their HIV-positive
partner, giving an estimated total of 8,965
instances of unprotected fellatio, with ejaculation
occurring in the mouth on an estimated 3,060
occasions (34%). Ninety-eight HIV-positive men
carried out unprotected cunnilingus on their HIV-
negative partner. Among the 25 HIV-negative
men with a positive partner, 12 had unprotected
cunnilingus, with an estimated 614 total number
of episodes. Twenty-four of the 25 men had pas-
sive fellatio, with a total of 1,081 instances of fel-
latio without a condom performed by the HIV-pos-
itive partner. In this study, over 19,000 instances
of unprotected oral sex did not lead to a single
case of HIV transmission. This data adds to the
growing number of studies that suggest a signifi-
cantly lower risk of HIV transmission from oral
sex as compared to anal or vaginal intercourse. It
is speculated that certain factors may increase
the risk of transmitting HIV via oral sex, such as
the HIV-positive person having a high viral load,
the HIV-infected person ejaculating into the
mouth of their partner, the presence of another
sexually transmitted disease, and poor oral
health. Although the authors concluded that study
results point to a very low probability of HIV trans-
mission related to oral sex, other STDs such as
syphilis and gonorrhea can be easily transmitted
in this manner.  
Romero J et al. Evaluating the risk of HIV trans-
mission through unprotected orogenital sex.
AIDS 16:9 1269-97, 2002.
Inside News
Resources
Updated Guidelinesfor the Use of Rifamycins
for the Treatment of Tuberculosis Among HIV-
Infected Patients Taking Protease Inhibitors or
Nonnucleoside Reverse Transcriptase Inhibitors
www.cdc.gov/nchstp/tb/TB_HIV_Drugs/TOC.htm
CDC Division of HIV/AIDS Prevention
www.cdc.gov/hiv/pubs/guidelines.htm
CDC National Center for Infectious Diseases:
Hepatitis C
www.cdc.gov/ncidod/diseases/hepatitis/c/
Hepatitis C Informational Brochure
http://www.harmreduction.org
The 32-page informational brochure is geared
toward drug users, and provides information
about HCV infection risks, prevention, screening,
and diagnosis. Copies are available as a free
PDF file or for 35 cents per printed pamphlet.
Call (212) 213-6376 x10 for more information. 
Body Pro CME/CE
www.thebodypro.com/cme/ 
A new way to earn CME or CE credits online.
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through August 31, 2004. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. Among patients with TB caused by drug-susceptible organ-
isms, the following characteristic has been found to be associat-
ed with an increased risk of relapse: 
a. Cavitary pulmonary disease on the initial chest radiograph 
b. Less than 21 years of age
c. Hispanic ethnicity 
d. Female gender 
2. For patients who have risk factors for the relapse for TB, the
recommended duration of the continuation phase of therapy is: 
a. Four months
b. Five months 
c. Seven months 
d. One year
3. In a supervised regimen for the treatment of TB, which of the
following agents can be dosed once-weekly:
a. Pyrazinamide
b. Rifabutin
c. Rifampin
d. Rifapentine 
4. Which of the following statements about the QuantiFERON®-
TB test (QFT) is false?
a. It requires phlebotomy
b. It can distinguish between responses to both M. 
tuberculosisand environmental mycobacteria.
c. It does not boost amnestic immune responses
d. It requires multiple patient visits
5. The Centers for Disease Control and Prevention recommends
that the combination of rifampin and pyrazinamide be used as
first line treatment for latent tuberculosis infection. 
a. True 
b. False
6. Which of the following statements is false: 
a. Rifampin increases the metabolism of nelfinavir 
b. When used in patients who are receiving Kaletra, the 
dose of rifabutin should be increased to 450 mg q day 
c. Efavirenz can be safely used in patients who are being 
treated with rifampin 
d.  Rifampin should not be given to patients who are 
receiving amprenavir or Kaletra 
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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